E
Elizabeth M. Anderson
Researcher at University of Pennsylvania
Publications - 38
Citations - 5508
Elizabeth M. Anderson is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Population & T cell. The author has an hindex of 22, co-authored 37 publications receiving 3702 citations. Previous affiliations of Elizabeth M. Anderson include The Catholic University of America & Western Washington University.
Papers
More filters
Journal ArticleDOI
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
Divij Mathew,Josephine R. Giles,Amy E. Baxter,Derek A. Oldridge,Allison R. Greenplate,Jennifer E. Wu,Cécile Alanio,Leticia Kuri-Cervantes,M. Betina Pampena,Kurt D'Andrea,Sasikanth Manne,Zeyu Chen,Yinghui Jane Huang,John P. Reilly,Ariel R. Weisman,Caroline A. G. Ittner,Oliva Kuthuru,Jeanette Dougherty,Kito Nzingha,Nicholas Han,Justin Kim,Ajinkya Pattekar,Eileen C. Goodwin,Elizabeth M. Anderson,Madison E. Weirick,Sigrid Gouma,Claudia P. Arevalo,Marcus J. Bolton,Fang Chen,Simon F. Lacey,Holly Ramage,Sara Cherry,Scott E. Hensley,Sokratis A. Apostolidis,Alexander C. Huang,Laura A. Vella,Laura A. Vella,Michael R. Betts,Nuala J. Meyer,E. John Wherry +39 more
TL;DR: High-dimensional flow cytometry of hospitalized COVID-19 patients found three prominent and distinct immunotypes that are related to disease severity and clinical parameters, and a compendium of immune cell information and roadmaps for potential therapeutic interventions is provided.
Journal ArticleDOI
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Nancie M. Archin,Abigail L. Liberty,Angela D. M. Kashuba,Shailesh K. Choudhary,Joann D. Kuruc,Amanda M. Crooks,Daniel C. Parker,Elizabeth M. Anderson,Mary F. Kearney,Matthew C. Strain,Douglas D. Richman,Michael G. Hudgens,Ronald J. Bosch,John M. Coffin,Joseph J. Eron,Daria J. Hazuda,David M. Margolis +16 more
TL;DR: It is demonstrated that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.
Journal ArticleDOI
Comprehensive mapping of immune perturbations associated with severe COVID-19.
Leticia Kuri-Cervantes,M. Betina Pampena,Wenzhao Meng,Aaron M. Rosenfeld,Caroline A. G. Ittner,Ariel R. Weisman,R.S. Agyekum,Divij Mathew,Amy E. Baxter,Laura A. Vella,Laura A. Vella,Oliva Kuthuru,Sokratis A. Apostolidis,Sokratis A. Apostolidis,Luanne Bershaw,Jeanette Dougherty,Allison R. Greenplate,Ajinkya Pattekar,Ajinkya Pattekar,Justin Kim,Nicholas Han,Sigrid Gouma,Madison E. Weirick,Claudia P. Arevalo,Marcus J. Bolton,Eileen C. Goodwin,Elizabeth M. Anderson,Scott E. Hensley,Tiffanie K. Jones,Nilam S. Mangalmurti,Eline T. Luning Prak,E. John Wherry,Nuala J. Meyer,Michael R. Betts +33 more
TL;DR: The neutrophil to lymphocyte ratio is found to be a prognostic biomarker of disease severity and organ failure and broad innate and adaptive leukocyte perturbations that distinguish dysregulated host responses in severe SARS-CoV-2 infection and warrant therapeutic investigation.
Journal ArticleDOI
Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo
Francesco R. Simonetti,Michele D. Sobolewski,Elizabeth Fyne,Wei Shao,Jonathan Spindler,Junko Hattori,Elizabeth M. Anderson,Sarah A. Watters,Shawn Hill,Xiaolin Wu,David Wells,Li Su,Brian T. Luke,Elias K. Halvas,Guillaume Besson,Kerri J. Penrose,Zhiming Yang,Richard Kwan,Carter Van Waes,Thomas S. Uldrick,Deborah Citrin,Joseph A. Kovacs,Michael A. Polis,Catherine Rehm,Robert J. Gorelick,Michael Piatak,Brandon F. Keele,Mary F. Kearney,John M. Coffin,Stephen H. Hughes,John W. Mellors,Frank Maldarelli +31 more
TL;DR: Results show that clonally expanded CD4+T cells can be a reservoir of infectious HIV-1, and it is reported that a highly expandedCD4+ T-cell clone contains an intact provirus.
Journal ArticleDOI
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
Elizabeth M. Anderson,Eileen C. Goodwin,Anurag Verma,Claudia P. Arevalo,Marcus J. Bolton,Madison E. Weirick,Sigrid Gouma,Christopher M McAllister,Shannon R. Christensen,JoEllen Weaver,Philip Hicks,Tomaz B. Manzoni,Oluwatosin Oniyide,Holly Ramage,Divij Mathew,Amy E. Baxter,Derek A. Oldridge,Allison R. Greenplate,Jennifer E. Wu,Cécile Alanio,Kurt D'Andrea,Oliva Kuthuru,Jeanette Dougherty,Ajinkya Pattekar,Justin Kim,Nicholas Han,Sokratis A. Apostolidis,Alexander C. Huang,Laura A. Vella,Laura A. Vella,Leticia Kuri-Cervantes,M. Betina Pampena,Michael R. Betts,E. John Wherry,Nuala J. Meyer,Sara Cherry,Paul Bates,Daniel J. Rader,Scott E. Hensley +38 more
TL;DR: In this paper, the authors quantified levels of SARS-CoV-2-reactive antibodies and hCoVreactive antibody in serum samples collected from 431 individuals before the COVID-19 pandemic, and then quantified pre-pandemic antibody levels in serum from a separate cohort of 251 individuals who became PCR-confirmed infected with SARS CoV 2.